

INVESTMENT STRATEGY

RTW Venture Fund Limited (the "Company" or LSE ticker symbol: "RTW") is focused on identifying companies developing transformative drug and medical technology products. RTW's approach is driven by applying deep scientific expertise with a long-term investment horizon. The Company is structured to optimize the ability to participate in value creation at any point beginning with company creation to late stage venture and into publicly traded markets. The Company's portfolio is managed by RTW Investments, LP, a leading healthcare investment firm with \$5.7B AUM and 39 professionals, the majority of whom have MD, PhD or other advanced scientific degrees, along with a team of seasoned operating executives, ex-bankers, and lawyers with corporate, capital markets and transaction experience.

FUND INFORMATION

Structure	Closed End Investment Fund	SEDOL	BKTRRM2	Administrator	Ocorian (Guernsey)
Domicile	Guernsey	ISIN	GG00BKTRRM22	Custodian	Barclays, Goldman Sachs
Listing	London Stock Exchange	Ticker	RTW.L	Registrar	Link Asset Managers
Website	www.rtwfunds.com/venture-fund/	Investment Manager	RTW Investments, LP	Corporate Broker	JPMorgan Cazenove, Barclays
Financial Year End	31 December				


MARKET VIEW

- Q4 2020 was a strong quarter for the healthcare sector with large-cap biotech heavy Nasdaq Biotechnology Index finishing the year +26.5% and small-cap biotech heavy Russell 2000 Biotechnology Index +52.6%.
- We believe the healthcare sector remains attractively valued, especially given the explosion in scientific innovation, and generalist interest just starting to return to the sector in the past year. The Covid vaccine experience brought some needed attention to how quickly new medicines can be discovered and developed leveraging genetic data and new drug technologies like mRNA.
- We think there are several exciting areas of significant innovation. In therapeutics, this includes RNA medicines, targeted oncology, gene therapy, and novel antibody-based drugs, and outside of drugs - molecular diagnostics, especially applied to cancer.


LATEST UPDATES

- In Q4 through Jan 2021, the Company announced investment participation alongside our affiliated funds in four biotech companies. New portfolio additions: **Prometheus**, a precision medicine biotech developing an anti-TL1A antibody for IBD; **Nuance Pharma**, a China-based specialty pharma focused on iron deficiency, pain management and respiratory conditions; **Biomea Fusion**, a targeted oncology biotech developing irreversible menin inhibitors; and an additional investment in existing portfolio company **Immunocore**, a T-cell receptor therapy company focused on oncology and infectious disease.
- In Dec 2020, **Rocket Pharmaceuticals**, the largest portfolio holding, shared positive data updates on four clinical programs with the share price trading +83% on the news, which translated into a materially accretive NAV performance for the Company.
- In 2020, in response to investor demand, the Company issued ~30M ordinary shares at premium to NAV, raising an additional US\$41.7M of non-dilutive capital.

PERFORMANCE ANALYSIS













NAV Performance as of 31 December 2020		Share Price Return Since Inception	80.8%
Net Asset Value	US\$375.3M	YTD NAV Return	53.9%
NAV Per Ordinary Share	US\$1.96	1 Month NAV Return	21.7%
Inception Date	30 October 2019	3 Month NAV Return	43.2%
NAV Return Since Inception	88.5%	Best Month	21.7%
Share Price	US\$1.88	Worst Month	-15.1%






















Monthly and Annual Performance Net of All Fees and Expenses

%	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	YTD
2020	-3.9%	-2.3%	-15.1%	7.4%	12.1%	9.4%	1.6%	3.6%	-2.7%	6.8%	10.2%	21.7%	53.9%
2019											11.5%	9.9%	22.5%

Performance updated through 31 December 2020 and is presented net of investment expenses, 1.25% management fee, and 20% annual performance allocation fee. Historical rates of return are not indicative of future results. The Nasdaq Biotechnology Index and Russell 2000 Biotech Index are included as benchmarks to show performance in the healthcare sector during the periods indicated. Comparisons to indices are provided for illustrative purposes only to show the general trend in the sector in the period indicated and are not intended to imply that the Company's portfolio was similar to the indices in either composition, volatility, or element of risk.

NEW INVESTMENTS		GROWING PORTFOLIO		
   	     	<p>4 INVESTMENTS ANNOUNCED</p>	<p>6 IPOs in 2020</p> <p>Six portfolio companies IPOed, with an average step-up to IPO of 1.8x, and first-day IPO performance of +38%</p>	<p>21 PORTFOLIO COMPANIES</p> <p>Launched with 6 portfolio companies, added 15 since IPO; Completed 16 private deals in 2020</p>

Portfolio Company	Public / Private*	Description	Lead program clinical stage	Expected upcoming catalyst	% NAV
 rocket	Public: "RCKT"	Gene therapy platform company for rare pediatric diseases. Five clinical programs for Fanconi anemia, Danon, LAD, PKD and IMO.	Phase 2	Update H1 2021	41.1%
 AVIDITY	Public: "RNA"	Antibody conjugated RNA medicines company. Lead program for myotonic dystrophy, a degenerative disease with no therapy.	Preclinical		3.9%
 Athira PHARMA	Public**: "ATHA"	Developer of innovative therapies to restore brain function in neurodegenerative diseases by targeting HGF/MET receptor.	Phase 2/3		2.5%
 tarsus	Public**: "TARS"	Clinical stage biotech developing first-in-class therapeutics for ophthalmic conditions.	Phase 3	H1 2021	2.5%
 C4 Therapeutics	Public**: "CCCC"	Targeted protein degradation company working on blood cancers.	Phase 1/2		2.3%
 FREQUENCY THERAPEUTICS	Public: "FREQ"	Lead drug designed to stimulate progenitor cells to differentiate into lost ear hair cells to treat noise-induced hearing loss.	Phase 2	Q1 2021	2.2%
RoyaltyCo	Private	RTW royalty holding vehicle; royalty as a part of RTW-Ji Xing-CYTK deal			2.0%
 IMMUNOCORE targeting T cell receptors	Private	T-cell receptor therapy company focused on oncology and infectious disease. Lead program for uveal melanoma.	Phase 3		1.7%
 JI XING 冀星 PHARMACEUTICALS	Private	NewCo focused on acquiring rights from innovative therapies in the West for development and commercialization in China.	Phase 2	Series B H1 2021	1.3%
 beta bionics	Private	Closed-loop pancreatic system for automated and autonomous delivery of insulin.	Pivotal	H1 2021	1.3%
 LANDOS PHARMA	Private	Developer of oral therapies for autoimmune disease. Lead program for inflammatory bowel disease.	Phase 2		1.1%
 pulmonX	Public**: "LUNG"	Commercializes Zephyr Valve, a first FDA approved minimally-invasive treatment for severe emphysema, a form of COPD.	Commercial		1.1%
Investment #21	Private	Preclinical stage biotech developing therapies that can address the underlying cause of heart disease ; lead asset gene therapy for HCM	Preclinical		1.1%
 iTeos Therapeutics	Public**: "ITOS"	Novel immune checkpoint company. Lead programs targeting TIGIT and A2A.	Phase 2	Q2 2021	1.0%
 Milestone PHARMACEUTICALS	Public: "MIST"	Clinical stage company developing interventions for tachycardias.	Phase 3		0.9%
 NKT	Private	Preclinical stage oncology biotech uses a structure-based design to develop small molecules against promising molecular targets.	Preclinical		0.6%
 Orchestra Biotek	Private	Sirolimus eluting balloon for the treatment of coronary and peripheral arterial disease.	Pivotal		0.6%
 Encoded THERAPEUTICS	Private	Gene therapy company developing one-time treatment for rare pediatric CNS disorders.	Preclinical		0.5%
 Prometheus Biosciences	Private	Precision medicine biotech developing an anti-TL1A antibody for IBD	Phase 1	Q1 2021	0.4%
 NUANCE PHARMA	Private	China-based specialty pharma focused on iron deficiency, pain management and respiratory conditions.	Phase 3		0.4%
 biomea FUSION	Private	Targeted oncology biotech developing irreversible menin inhibitor.	Preclinical		0.3%

*Based on 31 December 2020 valuation for private investments, ** subject to lockup, illiquidity discount Added since IPO

THIS FACTSHEET IS NOT INTENDED TO OFFER OR TO PROMOTE THE OFFER OR TRANSFER OF THE SHARES (THE "SHARES") OF RTW VENTURE FUND LIMITED (THE "COMPANY") IN THE UNITED STATES OR TO ANY "U.S. PERSONS" ("US PERSONS") AS DEFINED IN REGULATIONS UNDER THE US SECURITIES ACT OF 1933 (THE "SECURITIES ACT"). No part of this factsheet may be reproduced in any manner without the written permission of the Company. The possession or distribution of this factsheet in certain jurisdictions may be restricted by law and persons into whose possession this factsheet comes should inform themselves about and observe any applicable restrictions. This factsheet does not constitute or form a part of any offer to sell, or any solicitation of any offer to purchase or otherwise acquire, securities in any jurisdiction. The securities described in this factsheet may not be eligible for sale in certain jurisdictions or suitable for all types of investors. The Company has not been and will not be registered under the US Investment Company Act of 1940 (the "Investment Company Act") and the Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, transferred or delivered, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not require the Company to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. This factsheet was prepared using the financial and other information available to the Company and RTW Investments LP as at the date of this factsheet. The Shares are compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in EU Directive 2014/65/EU on markets and financial instruments, as amended (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, the Shares are traded on the Specialist Fund Segment of the London Stock Exchange, which is intended for institutional, professional, professionally advised, and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment. A key information document in respect of the Shares has been prepared by RTW Investments LP and is available to investors at www.rtwfunds.com/venturefund. This information in this document is believed to be accurate but has not been audited, reviewed or verified by any third party. This factsheet may describe past performance, which cannot be relied on as a guide to future performance. This factsheet may include statements regarding investment strategies, individual securities and economic and market conditions; however, there can be no guarantee that such statements will prove to be correct. This factsheet may include expressions of opinions that are speculative in nature and should not be relied on as statements of fact. This factsheet may include forward-looking statements which are subject to known and unknown risks and uncertainties that may cause actual results and events to differ materially from those expressed in or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by words like "will seek", "will target", "believe", "expect", "intend", or similar expressions. You should not place undue reliance on forward-looking statements. Each of the Company and RTW Investments, LP disclaim any obligation to update or alter any forward-looking statements whether as a result of new information, future events or otherwise. Neither the Company nor RTW Investments, LP accepts any liability for actions taken on the basis of the information provided in this factsheet. The information provided in this factsheet should not be considered a recommendation to buy, sell or hold any security.